These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 2670519)

  • 1. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.
    Hawthorne AB; Hawkey CJ
    Drugs; 1989 Aug; 38(2):267-88. PubMed ID: 2670519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug therapy of inflammatory bowel disease.
    Sack DM; Peppercorn MA
    Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
    Lamers CB; Griffioen G; van Hogezand RA; Veenendaal RA
    Scand J Gastroenterol Suppl; 1999; 230():111-5. PubMed ID: 10499471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammatory bowel diseases: conservative therapy].
    Bansky G
    Ther Umsch; 1991 Jul; 48(7):464-70. PubMed ID: 1926006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
    Su CG; Stein RB; Lewis JD; Lichtenstein GR
    Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of inflammatory bowel disease for the 21st century.
    Robinson M
    Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
    Schröder O; Stein J
    Am J Gastroenterol; 2003 Mar; 98(3):530-7. PubMed ID: 12650783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacotherapy of inflammatory bowel disease].
    Jojić N
    Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing conventional therapy for inflammatory bowel disease.
    Schwartz M; Cohen R
    Curr Gastroenterol Rep; 2008 Dec; 10(6):585-90. PubMed ID: 19006615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.